A new study found a low prevalence of physicians having advance care planning talks with their patients despite a steady growth in Medicare claims. The study, published Monday in the journal Health ...

- Pimavanserin as an adjunct to an antipsychotic showed significant improvements in the negative symptoms of schizophrenia vs. antipsychotic treatment alone - Pimavanserin well-tolerated among study ...

Since the rise of America's AIDS epidemic in the 80s, the FDA has banned men who have sex with men from donating blood. The rules have slightly been modified over time, but many believe the ...

Ralinepag has the potential to be the first once-a-day oral prostacyclin agonist for patients with pulmonary arterial hypertension ADVANCE OUTCOMES will continue to accrue clinical worsening events ...

WASHINGTON — Christian Morris will never forget the moment he realized he could not donate blood in high school. It was an experience he described as traumatizing. He learned the Food and Drug ...

Researchers at the University of Hawaiʻi at Mānoa have developed new mouse models to study a key male fertility gene, providing insights that could help scientists understand and eventually treat male ...

Researchers in the Hermelin Brain Tumor Center at Henry Ford Health are leading a Phase I clinical trial studying the maximum tolerated dose of an oncolytic adenovirus, a mutated virus engineered to ...

On Oct. 9, 2023, Harvard economist Claudia Goldin was awarded the Nobel Prize for her work in economics, for creating "the first comprehensive account of women's earnings and labor market ...

NEW YORK (Reuters Health) - U.S. laws surrounding advanced planning for end-of-life care set up too many practical roadblocks, according to a report published Monday. In a study of advance directive ...

Medical researchers have presented evidence for a shift to dolutegravir-containing antiretroviral treatment in South Africa. The South African study shows that dolutegravir-containing regimens perform ...

About ADVANCE OUTCOMES ADVANCE OUTCOMES is a global, multi-center, placebo-controlled phase 3 study evaluating an extended-release formulation of ralinepag, an oral, selective, potent, once-daily IP ...